Scott Leftwich - 28 Jun 2024 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)

Role: Director
Signature: /s/ Andrew Jackson, Attorney-in-fact
Issuer symbol: CLDI
Transactions as of: 28 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 02 Jul 2024, 20:22:46 UTC
Previous filing: 02 Jul 2024
Next filing: 15 Oct 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLDI	Common Stock	Award		+67,187	+14%		560,873	28 Jun 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a grant of restricted stock units ("RSUs") on June 28, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date.

Content

Represents a grant of restricted stock units ("RSUs") on June 28, 2024 (the "Grant Date"), pursuant to the Issuer's 2023 Equity Incentive Plan and subject to the conditions of a Restricted Stock Unit Award Agreement, in a transaction exempt under Rule 16b-3 to the Reporting Person, who is a non-employee director with the Issuer, in connection with services for the Issuer's second fiscal quarter. Each RSU represents a contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The RSUs fully vested on the Grant Date.

Remarks:

Exhibit 24 - Power of Attorney (previously filed as Exhibit 24 to Form 4 dated July 2, 2024.)